Drug intelligence / Profile preview

Pro-Z

Development stage: Preclinical
Lead developer: PBG BioPharma
Modality: Small Molecules
Administration: Topical

Overview

Pro-Z is a preclinical-stage pharmaceutical candidate being developed by Signal12 for the treatment of rhinosinusitis. As of early 2025, the drug is in the early planning or preclinical stages, with a development timeline projected to follow the regulatory progress of the company's lead candidate, Pro-ocular. While positioned as a prescription (Rx) therapy within Signal12's pipeline, specific details regarding its mechanism of action, molecular targets, and modality have not yet been publicly disclosed.

Other names: Pro-Z (Rx)

Beyond the preview

Go deeper on Pro-Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pro-Z.

Explore the full profile